Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abrocitinib Effects on Skin Barrier in Moderate to Severe Atopic Dermatitis
DRKS00028981Phase 4Completed
- Sponsor
- Universitätsklinikum Schleswig-Holstein
- Start
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of abrocitinib in atopic dermatitis (AD), sponsored by Universitätsklinikum Schleswig-Holstein. Started Dec 2022; status: completed.
02
Drugs
abrocitinib
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on DRKS00028981.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00028981.